ICYMI a recent #PrimaryCare #Diabetes study underlines the importance of further research into the underlying causes of #glycaemic control disparities and the development of tailored interventions to optimise #T2D care for all buff.ly/sQaz2P3

#Type2Diabetes #HealthEquity

A recent study in #PrimaryCare #Diabetes underlines the importance of further research into the underlying causes of #glycaemic control disparities and the development of tailored interventions to optimise #T2D care for all. buff.ly/sQaz2P3

#Type2Diabetes #HealthEquity

Amygdala–liver signalling orchestrates glycaemic responses to stress - Nature Studies in mice show that acute stress activates hyperglycaemia via activation of a medial amygdala–ventral hypothalamic circuit that controls glucose metabolic responses in the liver, independen...

#Amygdala – #liver signalling orchestrates #glycaemic responses to #stress
doi.org/10.1038/s415...

Infographic of a phase 2, double-blind, randomised trial on high-dose semaglutide (up to 16 mg) in 245 people with type 2 diabetes and BMI ≥27 kg/m² on metformin. Participants received once-weekly semaglutide or placebo for 40 weeks. Study arms: Placebo (n=60), 2 mg (n=61), 8 mg (n=62), 16 mg (n=62). HbA1c change (%): -1.0 (placebo), -1.8 (2 mg), -1.8 (8 mg), -2.1 (16 mg); 16 mg vs 2 mg: -0.3 (p=0.245). Weight change (kg): -2.6 (placebo), -8.3 (2 mg), -9.3 (8 mg), -11.7 (16 mg); 16 mg vs 2 mg: -3.4 (p=0.011). Gastrointestinal AEs: 34% (placebo), 47% (2 mg), 68% (8 mg), 71% (16 mg). Discontinuation: 2% (placebo), 7% (2 mg), 23% (8 mg), 18% (16 mg). Severe hypoglycaemia: 0% across all groups.

📟 A phase II study tested #GLP1 RA #semaglutide at doses of up to 16 mg - 8x the currently approved maximum.

First-author Vanita Aroda explains how it improves body weight and #glycaemic control, but at the cost of reduced tolerability.

Read more 👉 easd-elearning.eu/news/451/Hig...

#Diabetes #T2D

Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ability to perform self-care. Most diabetes guidelines focus on improving g...

#Glycaemic management strategies for #olderadults with type 1 & type 2 #diabetes not responding to their current regimen require an understanding of how & when to realign therapy to meet patient's current needs
www.thelancet.com/journals/lan...
#T1D #T2D
#FREE to read w/reg

#MedSky #EndoSky

A graph displaying the change in HbA1c levels over 52 weeks for IcoSema (dark blue) and Semaglutide 1.0 mg (light blue). The graph shows a greater reduction in HbA1c for IcoSema (-14.7 mmol/mol) compared to Semaglutide (-9.88 mmol/mol). The x-axis represents time in weeks (0 to 52), and the y-axis represents the change in HbA1c (mmol/mol). Data points with error bars indicate the trend of decreasing HbA1c levels over time, with IcoSema showing a steeper decline. A water droplet icon highlights the estimated mean change for each treatment.

A graph depicting the change in fasting blood glucose (FPG) levels over 52 weeks for IcoSema (dark blue) and Semaglutide 1.0 mg (light blue). IcoSema results in a greater reduction in FPG (-2.48 mmol/l) compared to Semaglutide (-1.43 mmol/l). The x-axis represents time in weeks (0 to 52), and the y-axis shows the change in FPG (mmol/l). Both treatments show an initial decline, with IcoSema achieving a steeper and more sustained reduction. A glucose monitor icon represents the estimated mean change for each treatment.

A graph illustrating the change in body weight over 52 weeks for IcoSema (dark blue) and Semaglutide 1.0 mg (light blue). Semaglutide leads to a significant weight reduction (-3.70 kg), while IcoSema results in a slight weight gain (+0.84 kg). The x-axis represents time in weeks (0 to 52), and the y-axis indicates the change in body weight (kg). The Semaglutide group shows a steady decrease in weight, while the IcoSema group experiences a slight increase. A scale icon with footprints visually represents the weight change for each treatment.

📊A recent phase III trial shows superior #glycaemic control with #IcoSema vs #Semaglutide.

“IcoSema provides a good balance between efficacy and safety while also reducing the total number of injections in a year,” the study authors write.

📰Read more👉 easd-elearning.eu/index.html@p...

#Diabetes

Poor #glycaemic control in type 2 #diabetes compromises leukocyte oxygen consumption rate, OXPHOS complex content and neutrophil- #endothelial interactions
www.sciencedirect.com/science/arti...

A promotional graphic featuring two professionals seated and engaged in discussion, with the EASD logo in the top right corner. The design includes audio waveforms and the text 'Complex diabetes cases in the Emergency Room' on a blue gradient background

🚨 #glycaemic #emergencies in Focus!🚨

Dr Aoife Egan & Dr Daniel Morganstein explore #diabetic ketoacidosis (#DKA) in #pregnancy, cancer therapy-induced crises & the need for multidisciplinary teamwork.

Listen now🎧👉https://www.easd.org/media-centre/podcasts.html

#Diabetes #care #research

The effect of altered #sleep timing on #glycaemic outcomes: Systematic review of human intervention studies

Acutely delaying sleep timing might have unfavourable effects on glycaemic outcomes, compared to (early) nighttime sleep.
dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/...